TrialLeukemia2009

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

A Cortelezzi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.